Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SNStanley NgJWJean WangJDJohn E. Dick

Discussion

Loading...

Member takes

Overview

Analysis shows that high gene expression correlates with improved tumor responsiveness in acute myeloid leukemia, indicating the Myelo-ID assay may aid treatment decisions.

Key Points

  • Tumor responsiveness was significantly predicted by elevated gene expression levels in acute myeloid leukemia, enhancing treatment precision.
  • High BCL2 gene expression was the principal indicator of patient survival, with median overall survival of 19.6 months versus 6.0 months for lower expression.
  • Myelo-ID assay was utilized to assess gene expression patterns, revealing striking insights into patient outcomes for those treated with hypomethylating agents and venetoclax.
  • The study underscores the utility of integrating rapid gene expression profiling into clinical assessments to guide therapeutic choices and improve patient outcomes.

Cite This Study

Ng et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d40dhttps://doi.org/10.1182/blood-2025-657
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrative Genomic and Immune Profiling to Identify and Characterize High-Risk Subgroups in Acute Myeloid Leukemia: Development of a 20-Gene Predictive Signature and Its Clinical Implications.2025 · 2 citations
  2. 2Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia2025
  3. 3Identifying treatment response in AML through a multi-omics classifier of malignant cell states2025
  4. 4Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia2025
  5. 5Proteogenomic analysis of NPM1-mutated AML reveals clinical heterogeneity related to differentiation states and mitochondrial metabolism2025